Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$3.45 - $8.77 $34,500 - $87,700
-10,000 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$8.01 - $12.84 $80,100 - $128,400
10,000 New
10,000 $81,000
Q3 2021

Nov 09, 2021

SELL
$11.94 - $16.09 $89,191 - $120,192
-7,470 Closed
0 $0
Q2 2021

Jul 08, 2021

SELL
$14.36 - $20.93 $132,672 - $193,372
-9,239 Reduced 55.29%
7,470 $113,000
Q1 2021

Jun 17, 2021

BUY
$18.19 - $33.25 $48,658 - $88,943
2,675 Added 19.06%
16,709 $310,000
Q4 2020

May 19, 2021

BUY
$15.87 - $31.64 $222,719 - $444,035
14,034 New
14,034 $64,000
Q3 2016

Sep 07, 2021

SELL
N/A
-247 Closed
0 $0
Q1 2016

Sep 07, 2021

BUY
N/A
247
247 $6,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.